---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116047"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:02:52.331100+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elutia closes Orthobiologics divestiture for up to $35M in cash proceeds

## Summary
- Upfront payment of $15M due Nov 17, 2023, plus up to $20M earnout over 5 years.
- Combined with Sept 2023 private placement, total potential cash exceeds $60M.
- Company refocuses on drug-eluting biomatrix platform, including CanGaroo RM.
- Transaction closed Nov 8; buyer is Berkeley Biologics (GNI Group subsidiary).
- Mizuho Securities acted as financial advisor; Kilpatrick Townsend as legal advisor.

## SEC filing metadata
- accession: 0001104659-23-116047
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465923116047/0001104659-23-116047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465923116047/tm2330025d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116047
- JSON: https://secwatch.observer/filing/0001104659-23-116047.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.